Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBRT + ipilimumab + sintilimab + nab-paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Shandong Cancer Hospital
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
"SBRT + ipilimumab + sintilimab + AG chemotherapy" is an investigational multi-modal combination regimen being evaluated for the treatment of locally advanced pancreatic cancer (LAPC). The regimen integrates stereotactic body radiotherapy (SBRT), a precise local ablative technique, with dual immune checkpoint blockade and cytotoxic chemotherapy. Ipilimumab (Yervoy) is a monoclonal antibody targeting CTLA-4, while sintilimab (Tyvyt) is a monoclonal antibody targeting PD-1. The "AG chemotherapy" component consists of nab-paclitaxel (Abraxane) and gemcitabine (Gemzar), which is a standard-of-care doublet for pancreatic cancer. This strategy aims to leverage the immunogenic cell death and local control provided by SBRT alongside systemic therapy to overcome the highly immunosuppressive microenvironment of pancreatic ductal adenocarcinoma. It is currently being studied in a Phase II clinical trial sponsored by the Shandong Cancer Hospital and Institute.
- Brand names
- AbraxaneGemzar
- Other names
- SBRT + Ipilimumab N01 + Sintilimab + AG ChemotherapyStereotactic Body Radiotherapy followed by Ipilimumab N01 plus Sintilimab in combination with Nab-Paclitaxel and Gemcitabine
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on SBRT + ipilimumab + sintilimab + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBRT + ipilimumab + sintilimab + nab-paclitaxel + gemcitabine.